Home › Companies › BridgeBio Pharma, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and BridgeBio Pharma, Inc.’s Form 8-K, filed June 26, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 22, 2026: 6 items on BridgeBio Pharma, Inc.’s Form 8-K, filed June 26, 2026: 3 approved · 3 passed (calculated).
Notable dissent: 1 director (19.9% against); 1 equity or compensation plan (17.1% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore BridgeBio Pharma, Inc. in the interactive database Compare manager voting policies
These tallies are BridgeBio Pharma, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 26, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: James C. Momtazee | 156,790,852 | -- | -- | 4,316,018 | 14,599,487 | 97% | Passed (calculated) | — |
| Elect Director: Frank P. McCormick, Ph.D. | 153,020,532 | -- | -- | 8,086,338 | 14,599,487 | 95% | Passed (calculated) | — |
| Elect Director: Hannah A. Valantine, M.D. | 129,081,930 | -- | -- | 32,024,940 | 14,599,487 | 80% | Passed (calculated) | — |
| 2. Non-binding Advisory Vote on Compensation of Named Executive Officers | 152,949,577 | 6,938,080 | 1,219,213 | -- | 14,599,487 | 96% | Approved | — |
| 4. Ratification of Appointment of Independent Registered Accounting Firm | 175,420,234 | 203,310 | 82,813 | -- | -- | 99.9% | Approved | — |
| 5. Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan | 132,402,786 | 27,350,537 | 1,353,547 | -- | 14,599,487 | 83% | Approved | — |
Source: BridgeBio Pharma, Inc., Form 8-K, filed with the SEC on June 26, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
465 asset managers disclosed a vote on at least one BridgeBio Pharma, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of BridgeBio Pharma, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 9 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly elected and qualified: Frank P. McCormick, Ph.D.
BridgeBio Pharma, Inc.’s own tally for this item (“Elect Director: Frank P. McCormick, Ph.D.”): 153,020,532 for, 8,086,338 withheld, per its Form 8-K filed June 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 125 asset managers below reported 61,342,754 for, 3,189,415 withheld, 86,559 abstained, 204 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,065,853 | 0 | 24 | 9,383 | For |
| Fidelity | 6,274,285 | 0 | 0 | 0 | For |
| BlackRock | 6,202,858 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 5,303,719 | 0 | 0 | 0 | For |
| Invesco | 3,054,107 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,714,068 | 0 | 0 | 0 | For |
| Charles Schwab | 1,969,410 | 0 | 0 | 447 | For |
| Delaware/Macquarie | 1,134,652 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 1,052,523 | 0 | 0 | 0 | For |
| Lord Abbett | 942,145 | 0 | 0 | 0 | For |
| American Century | 831,114 | 0 | 0 | 0 | For |
| JPMorgan | 809,854 | 0 | 0 | 0 | For |
| Capital Group | 763,702 | 0 | 0 | 0 | For |
| Principal | 458,236 | 0 | 0 | 257,703 | Mixed |
| Manager Directed Portfolios | 708,400 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 700,000 | 0 | 0 | 0 | For |
| Jackson National | 678,417 | 0 | 4,236 | 0 | For |
| Allspring | 649,905 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 637,808 | 0 | 0 | 0 | For |
| Equitable | 363,618 | 0 | 0 | 267,012 | Mixed |
| AllianceBernstein | 0 | 0 | 0 | 574,183 | Withhold |
| PRIMECAP Odyssey Funds | 479,080 | 0 | 0 | 0 | For |
| TIAA | 446,086 | 0 | 0 | 0 | For |
| Legg Mason | 442,542 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 437,130 | 0 | 0 | 0 | For |
Showing the 25 largest of 125 asset managers. All 125 are in the interactive database (link above).
Combines 9 wordings of this item as funds reported it.
80% Majority: yes · of votes cast
Description as filed by funds: To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly elected and qualified: Hannah A. Valantine, M.D.
BridgeBio Pharma, Inc.’s own tally for this item (“Elect Director: Hannah A. Valantine, M.D.”): 129,081,930 for, 32,024,940 withheld, per its Form 8-K filed June 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 125 asset managers below reported 52,311,370 for, 11,558,547 withheld, 748,812 abstained, 204 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,002,821 | 0 | 83 | 72,356 | For |
| Fidelity | 6,214,185 | 0 | 0 | 60,100 | For |
| BlackRock | 6,202,858 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 3,914,105 | 0 | 0 | 1,389,614 | Mixed |
| Invesco | 3,054,107 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,714,068 | 0 | 0 | 0 | For |
| Charles Schwab | 1,969,410 | 0 | 0 | 447 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 1,134,652 | Withhold |
| Columbia Threadneedle | 0 | 0 | 0 | 1,052,523 | Withhold |
| Lord Abbett | 942,145 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 831,114 | Withhold |
| JPMorgan | 809,854 | 0 | 0 | 0 | For |
| Capital Group | 763,702 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 715,939 | Withhold |
| Manager Directed Portfolios | 708,400 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 700,000 | 0 | 0 | 0 | For |
| Jackson National | 569,473 | 0 | 113,180 | 0 | Mixed |
| Allspring | 0 | 0 | 0 | 649,905 | Withhold |
| FRANKLIN STRATEGIC SERIES | 637,808 | 0 | 0 | 0 | For |
| Equitable | 363,618 | 0 | 0 | 267,012 | Mixed |
| AllianceBernstein | 0 | 0 | 0 | 574,183 | Withhold |
| PRIMECAP Odyssey Funds | 479,080 | 0 | 0 | 0 | For |
| TIAA | 446,086 | 0 | 0 | 0 | For |
| Legg Mason | 436,557 | 0 | 0 | 5,985 | For |
| MUTUAL FUND SERIES TRUST | 437,130 | 0 | 0 | 0 | For |
Showing the 25 largest of 125 asset managers. All 125 are in the interactive database (link above).
Combines 9 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly elected and qualified: James C. Momtazee
BridgeBio Pharma, Inc.’s own tally for this item (“Elect Director: James C. Momtazee”): 156,790,852 for, 4,316,018 withheld, per its Form 8-K filed June 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 125 asset managers below reported 62,663,287 for, 1,887,749 withheld, 67,692 abstained, 204 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,075,248 | 0 | 13 | 0 | For |
| Fidelity | 6,274,285 | 0 | 0 | 0 | For |
| BlackRock | 6,202,858 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 5,303,719 | 0 | 0 | 0 | For |
| Invesco | 3,054,107 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,714,068 | 0 | 0 | 0 | For |
| Charles Schwab | 1,969,857 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,134,652 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 1,052,523 | 0 | 0 | 0 | For |
| Lord Abbett | 942,145 | 0 | 0 | 0 | For |
| American Century | 831,114 | 0 | 0 | 0 | For |
| JPMorgan | 809,854 | 0 | 0 | 0 | For |
| Capital Group | 763,702 | 0 | 0 | 0 | For |
| Principal | 458,236 | 0 | 0 | 257,703 | Mixed |
| Manager Directed Portfolios | 708,400 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 700,000 | 0 | 0 | 0 | For |
| Jackson National | 678,417 | 0 | 4,236 | 0 | For |
| Allspring | 649,905 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 637,808 | 0 | 0 | 0 | For |
| Equitable | 363,618 | 0 | 0 | 267,012 | Mixed |
| AllianceBernstein | 0 | 0 | 0 | 574,183 | Withhold |
| PRIMECAP Odyssey Funds | 479,080 | 0 | 0 | 0 | For |
| TIAA | 446,086 | 0 | 0 | 0 | For |
| Legg Mason | 442,542 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 437,130 | 0 | 0 | 0 | For |
Showing the 25 largest of 125 asset managers. All 125 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
83% Approved · of votes cast
Description as filed by funds: To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 2,000,000 shares.
BridgeBio Pharma, Inc.’s own tally for this item (“5. Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan”): 132,402,786 for, 27,350,537 against — passed, per its Form 8-K filed June 26, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 5 - Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan The Company's stockholders approved the amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (th…”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 132 asset managers below reported 54,945,059 for, 9,610,820 against, 272,209 abstained, 204 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 16,996,255 | 79,002 | 4 | 0 | For |
| Fidelity | 6,214,185 | 60,100 | 0 | 0 | For |
| BlackRock | 6,202,858 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 3,914,105 | 1,389,614 | 0 | 0 | Mixed |
| Invesco | 3,054,107 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,714,068 | 0 | 0 | 0 | For |
| Charles Schwab | 1,969,857 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 1,134,652 | 0 | 0 | Against |
| Columbia Threadneedle | 1,052,523 | 0 | 0 | 0 | For |
| Lord Abbett | 942,145 | 0 | 0 | 0 | For |
| American Century | 0 | 831,114 | 0 | 0 | Against |
| JPMorgan | 809,854 | 0 | 0 | 0 | For |
| Capital Group | 0 | 763,702 | 0 | 0 | Against |
| Principal | 257,703 | 458,236 | 0 | 0 | Mixed |
| Manager Directed Portfolios | 708,400 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 700,000 | 0 | 0 | 0 | For |
| Jackson National | 639,139 | 43,514 | 0 | 0 | Mixed |
| Allspring | 0 | 649,905 | 0 | 0 | Against |
| FRANKLIN STRATEGIC SERIES | 637,808 | 0 | 0 | 0 | For |
| Equitable | 630,630 | 0 | 0 | 0 | For |
| AllianceBernstein | 574,183 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 479,080 | 0 | 0 | 0 | For |
| TIAA | 446,086 | 0 | 0 | 0 | For |
| Legg Mason | 436,557 | 5,985 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 437,130 | 0 | 0 | 0 | For |
Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).
Combines 13 wordings of this item as funds reported it.
96% Approved · of votes cast
Prior year: 75.6% for (June 20, 2025 meeting) ▲ 20.0 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.
BridgeBio Pharma, Inc.’s own tally for this item (“2. Non-binding Advisory Vote on Compensation of Named Executive Officers”): 152,949,577 for, 6,938,080 against — passed, per its Form 8-K filed June 26, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,075,248 | 10 | 4 | 0 | For |
| Fidelity | 6,274,285 | 0 | 0 | 0 | For |
| BlackRock | 6,202,858 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 5,303,719 | 0 | 0 | 0 | For |
| Invesco | 15,953 | 3,038,154 | 0 | 0 | Against |
| T. Rowe Price | 2,714,068 | 0 | 0 | 0 | For |
| Charles Schwab | 1,969,857 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,134,652 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 1,052,523 | 0 | 0 | 0 | For |
| Lord Abbett | 942,145 | 0 | 0 | 0 | For |
| American Century | 831,114 | 0 | 0 | 0 | For |
| JPMorgan | 809,854 | 0 | 0 | 0 | For |
| Capital Group | 0 | 763,702 | 0 | 0 | Against |
| Principal | 715,939 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 708,400 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 700,000 | 0 | 0 | 0 | For |
| Jackson National | 285,365 | 397,288 | 0 | 0 | Mixed |
| Allspring | 649,905 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 637,808 | 0 | 0 | 0 | For |
| Equitable | 630,630 | 0 | 0 | 0 | For |
| AllianceBernstein | 574,183 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 479,080 | 0 | 0 | 0 | For |
| TIAA | 446,086 | 0 | 0 | 0 | For |
| Legg Mason | 442,542 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 437,130 | 0 | 0 | 0 | For |
Fund voting reports, all 123 managers: 59,858,396 for, 4,534,345 against, 40,813 abstained, 204 not voted. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 18,435,196 | 0 | 0 | 0 | For |
| Kohlberg Kravis Roberts & Co. L.P. | 13,260,971 | 0 | 0 | 0 | For |
| VIKING GLOBAL INVESTORS LP | 11,763,175 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 5,740,639 | 0 | 0 | 0 | For |
| BlackRock | 5,255,542 | 373 | 0 | 0 | For |
| Aisling Capital Management LP | 5,089,611 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 4,844,082 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 4,789,422 | 0 | 0 | 0 | For |
| Invesco | 15,953 | 4,097,429 | 0 | 0 | Against |
| T. Rowe Price | 3,558,031 | 0 | 0 | 0 | For |
| State Street | 3,482,103 | 0 | 0 | 0 | For |
| Fidelity | 2,340,837 | 88 | 0 | 0 | For |
| Charles Schwab | 1,997,571 | 0 | 0 | 0 | For |
| John Hancock | 1,944,652 | 0 | 0 | 0 | For |
| SC US (TTGP), LTD. | 1,874,034 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 1,853,763 | 0 | 0 | 0 | For |
| Wellington | 1,734,554 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,723,954 | 0 | 0 | 0 | For |
| Vanguard | 1,434,406 | 0 | 0 | 0 | For |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 1,292,197 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,241,572 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 1,140,433 | 0 | 0 | 0 | For |
| LORD, ABBETT & CO. LLC | 1,077,243 | 0 | 0 | 0 | For |
| Clearbridge Investments, LLC | 1,005,708 | 0 | 0 | 0 | For |
| DE Shaw | 976,535 | 0 | 0 | 0 | For |
Institutional-manager reports, all 372 managers: 118,499,568 for, 5,956,173 against, 2,709 not voted, 664,940 mixed, 37,672 1 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
100% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| JANUS INVESTMENT FUND | 0 | 0 | 0 | 0 | -- |
| Invesco | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | Not Voted |
| Delaware/Macquarie | 0 | 0 | 0 | 0 | -- |
| Columbia Threadneedle | 0 | 0 | 0 | 0 | -- |
| Lord Abbett | 0 | 0 | 0 | 0 | -- |
| American Century | 0 | 0 | 0 | 0 | -- |
| JPMorgan | 0 | 0 | 0 | 0 | -- |
| Capital Group | 0 | 0 | 0 | 0 | -- |
| Principal | 0 | 0 | 0 | 0 | -- |
| Manager Directed Portfolios | 0 | 0 | 0 | 0 | -- |
| Franklin Custodian Funds | 0 | 0 | 0 | 0 | -- |
| Jackson National | 0 | 0 | 0 | 0 | -- |
| Allspring | 0 | 0 | 0 | 0 | -- |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| AllianceBernstein | 0 | 0 | 0 | 0 | -- |
| PRIMECAP Odyssey Funds | 0 | 0 | 0 | 0 | -- |
| TIAA | 0 | 0 | 0 | 0 | -- |
| Legg Mason | 0 | 0 | 0 | 0 | -- |
| MUTUAL FUND SERIES TRUST | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 120 managers: 167,160 for, 40,809 abstained, 204 not voted, 63,814,167 1 year, 248,551 3 year, 29,693 unknown. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 0 | 0 | 0 | 0 | -- |
| Kohlberg Kravis Roberts & Co. L.P. | 0 | 0 | 0 | 0 | -- |
| VIKING GLOBAL INVESTORS LP | 0 | 0 | 0 | 0 | -- |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 5,740,639 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Aisling Capital Management LP | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| Polar Capital Holdings Plc | 0 | 0 | 0 | 0 | -- |
| Invesco | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | Not Voted |
| John Hancock | 0 | 0 | 0 | 0 | -- |
| FRANKLIN ADVISERS INC | 0 | 0 | 0 | 0 | -- |
| Wellington | 0 | 0 | 0 | 0 | -- |
| AllianceBernstein | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 0 | 0 | 0 | 0 | -- |
| PICTET ASSET MANAGEMENT SA | 0 | 0 | 0 | 0 | -- |
| Hood River Capital Management LLC | 0 | 0 | 0 | 0 | -- |
| LORD, ABBETT & CO. LLC | 0 | 0 | 0 | 0 | -- |
| Clearbridge Investments, LLC | 0 | 0 | 0 | 0 | -- |
| DE Shaw | 0 | 0 | 0 | 0 | -- |
| American Century | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 355 managers: 5,954,576 for, 1,327 not voted, 110,174,062 1 year, 5,089,843 2 year, 1,125,454 3 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 100.0% for (June 20, 2025 meeting) ▼ 0.1 pts
Description as filed by funds: To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.
BridgeBio Pharma, Inc.’s own tally for this item (“4. Ratification of Appointment of Independent Registered Accounting Firm”): 175,420,234 for, 203,310 against — passed, per its Form 8-K filed June 26, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 124 asset managers below reported 64,175,657 for, 4,275 against, 40,809 abstained, 204 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,075,261 | 0 | 0 | 0 | For |
| Fidelity | 6,274,285 | 0 | 0 | 0 | For |
| BlackRock | 6,202,858 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 5,303,719 | 0 | 0 | 0 | For |
| Invesco | 3,054,107 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,714,068 | 0 | 0 | 0 | For |
| Charles Schwab | 1,969,857 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,134,652 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 1,052,523 | 0 | 0 | 0 | For |
| Lord Abbett | 942,145 | 0 | 0 | 0 | For |
| American Century | 831,114 | 0 | 0 | 0 | For |
| JPMorgan | 809,854 | 0 | 0 | 0 | For |
| Capital Group | 763,702 | 0 | 0 | 0 | For |
| Principal | 715,939 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 708,400 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 700,000 | 0 | 0 | 0 | For |
| Jackson National | 682,653 | 0 | 0 | 0 | For |
| Allspring | 649,905 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 637,808 | 0 | 0 | 0 | For |
| Equitable | 630,630 | 0 | 0 | 0 | For |
| AllianceBernstein | 574,183 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 479,080 | 0 | 0 | 0 | For |
| TIAA | 446,086 | 0 | 0 | 0 | For |
| Legg Mason | 442,542 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 437,130 | 0 | 0 | 0 | For |
Showing the 25 largest of 124 asset managers. All 124 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 195,707,702 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 8.72% |
| 2 | Fidelity | 3.21% |
| 3 | BlackRock | 3.17% |
| 4 | JANUS INVESTMENT FUND | 2.71% |
| 5 | Invesco | 1.56% |
| 6 | T. Rowe Price | 1.39% |
| 7 | Charles Schwab | 1.01% |
| 8 | Delaware/Macquarie | 0.58% |
| 9 | Columbia Threadneedle | 0.54% |
| 10 | Lord Abbett | 0.48% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Janus Henderson | 9.42% |
| 2 | Kohlberg Kravis Roberts & Co. L.P. | 6.78% |
| 3 | VIKING GLOBAL INVESTORS LP | 6.01% |
| 4 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 2.93% |
| 5 | BlackRock | 2.69% |
| 6 | Aisling Capital Management LP | 2.60% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.48% |
| 8 | Polar Capital Holdings Plc | 2.45% |
| 9 | Invesco | 2.10% |
| 10 | T. Rowe Price | 1.82% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Vanguard Group | 16,862,691 | 8.62% | Form 13F, quarter ended March 31, 2026 |
| BlackRock | 14,207,757 | 7.26% | Form 13F, quarter ended March 31, 2026 |
| Ali J. Satvat | 13,802,496 | 7.05% | Proxy statement (DEF 14A), table as of April 1, 2026 |
| KKR Genetic Disorder L.P. | 13,260,971 | 6.78% | Proxy statement (DEF 14A), table as of April 1, 2026 |
| JANUS HENDERSON GROUP PLC | 13,179,013 | 6.73% | Schedule 13G, filed May 15, 2026 |
| Viking Global Entities | 11,842,434 | 6.05% | Proxy statement (DEF 14A), table as of April 1, 2026 |
| VIKING GLOBAL INVESTORS LP | 9,792,219 | 5.00% | Schedule 13D, filed July 10, 2026 |
| NEIL KUMAR | 9,282,982 | 4.74% | Schedule 13G, filed April 16, 2026 |
| KKR Group Partnership L.P. | 9,232,739 | 4.72% | Schedule 13D, filed August 17, 2026 |
| State Street | 4,934,320 | 2.52% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 195,707,702 shares outstanding, as reported by BridgeBio Pharma, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At BridgeBio Pharma, Inc.'s shareholder meeting held June 22, 2026, in the 2025-2026 proxy season, 465 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 4,402 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — BridgeBio Pharma, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BridgeBio Pharma, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 26, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BridgeBio Pharma, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
BridgeBio Pharma, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “BridgeBio Pharma (BBIO) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/bridgebio-pharma-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.